2022
DOI: 10.3390/jcm11143970
|View full text |Cite
|
Sign up to set email alerts
|

The “FIFTY SHADOWS” of the RALES Trial: Lessons about the Potential Risk of Dietary Potassium Supplementation in Patients with Chronic Kidney Disease

Abstract: Hyperkalaemia (HK) is one of the most common electrolyte disorders and a frequent reason for nephrological consultations. High serum potassium (K+) levels are associated with elevated morbidity and mortality, mainly due to life-threatening arrhythmias. In the majority of cases, HK is associated with chronic kidney disease (CKD), or with the use of renin–angiotensin–aldosterone system inhibitors (RAASis) and/or mineral corticoid antagonists (MRAs). These drugs represent the mainstays of treatment in CKD, HF, di… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 73 publications
0
1
0
Order By: Relevance
“…Similarly, the reduction of albuminuria is observed with the use of eplerenone [111]. However, these drugs are relatively or strongly contraindicated in patients with advanced CKD, in part due to the increased risk of hyperkalemia [112,113]. Recently, a new non-steroidal MRA, finerenone, has emerged.…”
Section: Mineralocorticoid Receptor Antagonistmentioning
confidence: 97%
“…Similarly, the reduction of albuminuria is observed with the use of eplerenone [111]. However, these drugs are relatively or strongly contraindicated in patients with advanced CKD, in part due to the increased risk of hyperkalemia [112,113]. Recently, a new non-steroidal MRA, finerenone, has emerged.…”
Section: Mineralocorticoid Receptor Antagonistmentioning
confidence: 97%